> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Equipment Contamination Seen in 2 Aurobindo Inspections
- URL: https://www.fdaweb.com/equipment-contamination-seen-in-2-aurobindo-inspections/
- Published: 2019-11-07T12:00:00.000Z
- Updated: 2026-09-14T15:52:17.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145451

An FDA October inspection at two Aurobindo Pharmaceutical drug manufacturing facilities in Hyderabad, India, raised concerns about contamination of equipment. *The News Minute*, an online India news source, [reports](https://www.thenewsminute.com/article/aurobindo-pharmaceuticals-under-us-scanner-unhygienic-equipment-2-hyd-units-111906?ref=fdaweb.com) that the U.S. agency “raised concerns over the lack of hygiene and cleanliness at these facilities.”

The online post says there has been no comment from FDA or Aurobindo on the potency of the drugs produced in the unhygienic facilities.

Earlier in the month, FDA reportedly issued a Warning Letter to Aurobindo after several of the company’s data records pertaining to quality control and checks were found to be incomplete or irregular, raising concerns over the effectiveness or potency of the drugs.